The biggest breast cancer meeting of the year is in full swing, but don’t worry if you couldn’t make it to the San Antonio Breast Cancer Symposium 2016 because we’ve got some highlights for you! We’ll be updating this page every day with new information from just a few of the sessions at this year’s conference.
In the first general session yesterday (Wednesday) morning, the results from the NSABP-B42 trial were presented by Eleftherios Mamounas and Norman Wolmark. NSABP-B43 was a randomised trial involving postmenopausal women who had already received five years of endocrine therapy with tamoxifen or aromatase inhibitors (AI), and saw some participants receive extended letrozole for five years, while the control group received a placebo. There was a small benefit in disease free survival, 84% VS 81%, but 40% of women discontinued extended treatment.
The results presented showed that there was small or no benefit in extending AI treatment if the patient had received it previously. Despite a reduction in distant metastasis, extended AI treatment had no impact on overall survival and there was no suggestion that one subgroup benefitted more than another (for example, node positive or large tumours).
Professor Diana Eccles presented data from the POSH study of women aged 40 or under with invasive breast cancer, which demonstrated no difference in outcome in those who were BRCA gene carriers and those who were not. However, in the triple negative subgroup, the outcome is better in the BRCA subgroup.
More updates will be posted here in due course.